|
| Home : Interface Biologics Announces Series B Financing Round With DSM and BDC Capital |
|
Jan 14
2015 |
Interface Biologics Announces Series B Financing Round With DSM and BDC Capital |
|
TORONTO, ONTARIO--(Marketwired - Jan. 13, 2015) - Interface Biologics Inc. (IBI), an innovative developer of biomedical-polymer technologies which improve the safety and effectiveness of medical devices, is pleased to announce the completion of a Series B financing round led by DSM Venturing and existing investor, BDC Capital. |
|
|
|
| Source:http://www.marketwired.com/mw/release.do?id=1982349&sourceType=3 |
| |
|
Related News
|
» Hornby Bay Closes Previously Announced $100,000 Convertible Promissory Note Financing
» Security Holding in Euromax Resources Ltd
|
|
|
